We performed the overall survival analyses in different grades and different molecular subtypes of glioma to further explore the prognostic value of MAPKAPK2. High levels of MAPKAPK2 correlated with poor prognosis of glioma patients with grade 2 and grade 3 glioma in TCGA and the patients with GBM in CGGA batches 1 and 2 (Figures 3K, L–O). This evidence concerns the gene MAPKAPK2 and central nervous system cancer.